Overview Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects Status: Completed Trial end date: 2017-04-01 Target enrollment: Participant gender: Summary A study to Establish Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects. Phase: Phase 2 Details Lead Sponsor: Orasis Pharmaceuticals Ltd.